GREENWICH, Conn., Feb. 20, 2012 /PRNewswire-Asia/ -- Aptuit
announces the completion of the sale of the Clinical Trials Supply
business to Catalent Pharma Solutions on February 17, 2012. Timothy
C. Tyson, Chairman and CEO of Aptuit, LLC stated that Aptuit will
continue to deliver scientific and service excellence to provide
integrated capabilities for the early to mid phase drug development
markets.
(Logo: http://photos.prnewswire.com/prnh/20120217/NY55633LOGO
)
Mr. Tyson explained, "We have assembled a team comprised of some of
the foremost scientific professionals in the industry. As part of
our ongoing mission to engineer a better drug development process,
we previously implemented a service performance initiative that
drives every level of our organization. Today, Aptuit people are
joining their 'heads for science' and their 'hearts for service' to
continue to provide scientific excellence and a level of service
that goes above and beyond what has come to be the industry
standard."
Early to mid-phase services
Aptuit's early to mid-phase development services include Drug
Design and Discovery, Solid State Chemistry, Preclinical
Biosciences, API Development and Manufacture, Solid, Oral and
Sterile Dosage Formulation, Clinical Sciences, Consulting Services
and Aptuit INDiGO(TM), our proprietary program for fast track IND
submission. Mr. Tyson noted Aptuit's best in class position in
several of these key development areas, specifically citing the
company's solid state chemistry, high potency API, accelerated
development and lead optimization capabilities.
Integrated or stand alone services
Stuart E. Needleman, President, Aptuit Scientific Operations,
stressed that Aptuit has a team of scientific professionals in
place who speak the client's language. He explained that they have
extensive experience in working with multinational clients and
emerging biotechs, and a track record for delivering on time and in
full. "We thoroughly understand that business goals and scientific
objectives vary greatly from client to client. That's why we are
flexible in offering our clients an Integrated Service Package,
consisting of all-inclusive early to mid-phase development services
from a single Aptuit location, or stand alone services that are
tailored to precisely meet their unique requirements," said Mr.
Needleman.
The global scientific team led by a new CSO
The appointment of a Chief Scientific Officer (CSO) was cited as an
example of the company's focus on scientific excellence. Mr.
Needleman said, "The recent appointment of Dr. Jan-Olav Henck, a
world renowned solid state chemist with significant industry
experience, is another indication of how Aptuit customers benefit
from the leadership and collaboration of some of the industry's
most distinguished and experienced scientific minds." He further
explained that while Aptuit scientists offer drug development
expertise across all therapeutic areas, the company includes
technical teams of scientific medical specialists who are focused
on diseases and therapies that drive the current market, including
neuroscience, cardiovascular, oncology and infectious
disease.
In discussing Aptuit's strategically positioned global resources,
Mr. Needleman cited Aptuit's world class drug design and
optimization facility in Verona, Italy. "While the special
strengths of some of our individual global facilities such as
Verona are a decided advantage, we are a capability-centric
organization: we focus on our client's needs," said Mr. Needleman.
He added that all sites adhere to the same high quality standards
of regulatory compliance.
In conclusion, Mr. Tyson said, "Aptuit continues to be a
world-leading pharmaceutical services company, well-positioned for
the dynamic growth projected in this market. We plan to invest for
growth, continue our passion for scientific excellence and deliver
on exceptional customer service."
For more information, please contact Maria Garvey, Delfino
Marketing at 914-747-1400 or [email protected] or Paul Delfino at
914-494-4679 or email him at [email protected]
Aptuit is a global pharmaceutical services company focusing on
delivering contract development and manufacturing services and
streamlining the drug development process for biotechnology and
pharmaceutical innovators. Aptuit's employees deliver an integrated
suite of product development services to more than 800 companies
worldwide driven by a deep commitment to client service, quality
and an unrivaled track record of scientific excellence. The company
is partnered with Welsh, Carson, Anderson & Stowe, one of the
world's leading private equity investors. For more information
about Aptuit, visit www.aptuit.com
Aptuit: engineering a better drug development process through
scientific excellence
SOURCE﹛Aptuit